Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report)'s stock price traded down 3.4% during trading on Tuesday . The stock traded as low as $3.71 and last traded at $3.69. 710 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 14,961 shares. The stock had previously closed at $3.82.
Wall Street Analyst Weigh In
Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a research note on Tuesday, March 11th. They set an "outperform" rating and a $12.00 target price on the stock.
Get Our Latest Stock Report on MOLN
Molecular Partners Stock Performance
The stock has a market cap of $150.20 million, a P/E ratio of -1.94 and a beta of 1.10. The firm has a 50-day moving average price of $3.86 and a 200-day moving average price of $4.41.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.11). On average, research analysts predict that Molecular Partners AG Sponsored ADR will post -1.93 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Molecular Partners stock. BVF Inc. IL grew its holdings in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) by 205.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,353,968 shares of the company's stock after purchasing an additional 910,747 shares during the period. BVF Inc. IL owned approximately 3.35% of Molecular Partners worth $6,458,000 as of its most recent SEC filing. 26.55% of the stock is owned by hedge funds and other institutional investors.
About Molecular Partners
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
